Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18713225 | Acetoacetate Based Ketals | May 2024 | January 2026 | Abandon | 19 | 2 | 0 | Yes | No |
| 18180472 | METHODS, DOSAGE REGIMENS, AND COMPOSITIONS FOR TREATING HIDRADENITIS | March 2023 | February 2026 | Abandon | 35 | 2 | 1 | No | No |
| 18179025 | PURE FORMS OF CRYSTALLINE ATICAPRANT | March 2023 | October 2025 | Abandon | 32 | 1 | 1 | No | No |
| 18043146 | COMPOUNDS AND FORMULATIONS FOR TREATING OPHTHALMIC DISEASES | February 2023 | January 2026 | Allow | 35 | 0 | 1 | No | No |
| 18163171 | PHARMACEUTICAL FORMULATIONS CONTAINING NALBUPHINE | February 2023 | August 2025 | Allow | 31 | 2 | 1 | Yes | No |
| 17998244 | SOS1 INHIBITOR CONTAINING PHOSPHORUS | November 2022 | November 2025 | Allow | 36 | 0 | 1 | Yes | No |
| 17920866 | KRAS G12D PROTEIN INHIBITORS | October 2022 | January 2026 | Allow | 39 | 1 | 0 | No | No |
| 17916476 | N-(HETEROCYCLYL AND HETEROCYCLYLALKYL)-3-BENZYLPYRIDIN-2-AMINE DERIVATIVES AS SSTR4 AGONISTS | September 2022 | June 2025 | Allow | 32 | 0 | 1 | No | No |
| 17914052 | METHOD FOR TREATING CANCER | September 2022 | January 2026 | Allow | 40 | 1 | 1 | Yes | No |
| 17912597 | USE OF BUCILLAMINE IN THE TREATMENT OF INFECTIOUS DISEASES | September 2022 | February 2026 | Abandon | 41 | 1 | 0 | No | No |
| 17904159 | THERAPEUTIC COMBINATIONS COMPRISING UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS AND POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | August 2022 | January 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17760347 | METHODS OF TREATING PSEUDOBULBAR AFFECT AND OTHER EMOTIONAL DISTURBANCES | August 2022 | February 2026 | Abandon | 42 | 3 | 0 | Yes | No |
| 17759890 | [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS | August 2022 | January 2026 | Abandon | 42 | 0 | 1 | No | No |
| 17790569 | NEW PqsR INVERSE AGONISTS | July 2022 | October 2025 | Allow | 40 | 1 | 1 | No | No |
| 17854755 | Treatment of EGFR-Driven Cancer with Fewer Side Effects | June 2022 | August 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17787940 | COMPOUND USED AS KINASE INHIBITOR AND USE THEREOF | June 2022 | February 2026 | Abandon | 44 | 2 | 1 | No | No |
| 17783940 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | June 2022 | September 2025 | Allow | 40 | 1 | 1 | Yes | No |
| 17783947 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | June 2022 | September 2025 | Allow | 39 | 1 | 1 | Yes | No |
| 17782889 | NOVEL SUBSTITUTED 1,3-8-TRIAZASPIRO[4,5] DECANE-2,4-DIONE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) AND/OR TRYPTOPHAN 2,3-DIOXYGENASE (TDO) INHIBITORS | June 2022 | August 2025 | Allow | 38 | 1 | 1 | Yes | No |
| 17782091 | COMPOSITIONS COMPRISING PKC-BETA INHIBITORS AND PROCESSES FOR THE PREPARATION THEREOF | June 2022 | August 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17779826 | USE OF COMPOSITION FOR ENHANCING ANTICANCER EFFECT, COMPRISING ERRy INHIBITOR AS ACTIVE INGREDIENT | May 2022 | March 2026 | Allow | 45 | 1 | 1 | No | No |
| 17767547 | SULFONAMIDE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | April 2022 | September 2025 | Allow | 42 | 1 | 1 | Yes | No |
| 17754632 | SUBSTITUTED NITROGEN HETEROCYCLIC COMPOUND AND ANESTHETIC EFFECT THEREOF | April 2022 | October 2025 | Allow | 42 | 2 | 1 | Yes | No |
| 17766392 | SUBSTITUTED CARBAZOLE COMPOUNDS | April 2022 | April 2025 | Allow | 36 | 0 | 1 | Yes | No |
| 17765755 | PROCESS FOR PREPARING AN ACTIVIN RECEPTOR-LIKE KINASE INHIBITOR | March 2022 | February 2026 | Allow | 47 | 1 | 1 | Yes | No |
| 17640978 | PHARMACEUTICAL COMBINATIONS COMPRISING A FURAZANOBENZIMIDAZOLES AND A CD40 AGONIST FOR USE IN THE TREATMENT OF NEOPLASTIC DISEASES | March 2022 | October 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17639065 | GENETIC VARIANTS FOR DIAGNOSIS OF ALZHEIMER'S DISEASE | February 2022 | July 2025 | Allow | 40 | 0 | 1 | Yes | No |
| 17637044 | BENZAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | February 2022 | February 2026 | Allow | 48 | 2 | 1 | Yes | No |
| 17597897 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | January 2022 | June 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17630414 | DEUTERATED MK2 PATHWAY INHIBITORS AND METHODS OF USING THE SAME | January 2022 | May 2025 | Allow | 39 | 1 | 0 | Yes | No |
| 17581520 | PYRIDINE DERIVATIVES AS CALCIUM-ACTIVATED CHLORIDE CHANNEL MODULATORS | January 2022 | October 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17628946 | MODULATORS OF TREX1 | January 2022 | September 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17628947 | CRYSTALLINE FORMS OF 7-CHLORO-2-(4-(3-METHOXYAZETIDIN-1-YL)CYCLOHEXYL)-2,4-DIMETHYL-N-((6-METHYL-4-(METHYLTHIO)-2-OXO-1,2-DIHYDROPYRIDIN-3-YL)METHYL)BENZO[D][1,3]DIOXOLE-5-CARBOXAMIDE | January 2022 | August 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17576144 | TRIARYL COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES | January 2022 | July 2025 | Allow | 42 | 1 | 1 | No | No |
| 16629491 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | January 2022 | December 2025 | Allow | 60 | 2 | 1 | No | No |
| 17569255 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | January 2022 | November 2024 | Allow | 35 | 0 | 0 | Yes | No |
| 17618541 | METHODS OF GENERATING OLIGODENDROCYTES | December 2021 | February 2026 | Allow | 50 | 2 | 1 | Yes | No |
| 17596224 | REVERSIBLE CULTURAL RELIC PROTECTION MATERIAL WITH FUNCTION OF INHIBITING GROWTH OF BACTERIA AND MOLD | December 2021 | June 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17615377 | BAX INHIBITORS AND USES THEREOF | November 2021 | July 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17595516 | DIETARY BUTYRATE AND ITS USES | November 2021 | March 2026 | Allow | 51 | 2 | 1 | Yes | Yes |
| 17610879 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISEASE USING AUTOPHAGY ACTIVATION | November 2021 | May 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17608820 | METHODS FOR TREATING SARCOIDOSIS-ASSOCIATED PULMONARY HYPERTENSION | November 2021 | June 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17593923 | OSIMERTINIB FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER | September 2021 | July 2025 | Allow | 45 | 1 | 1 | No | No |
| 17310151 | HIGH CONCENTRATION VITAMIN C TOPICAL COMPOSITIONS AND METHOD OF MAKING SAME | July 2021 | December 2025 | Allow | 53 | 2 | 1 | No | No |
| 17422689 | PHOSPHONATE CONJUGATES AND USES THEREOF | July 2021 | November 2025 | Allow | 52 | 2 | 1 | Yes | No |
| 17420307 | CONJUGATES OF PATTERN RECOGNITION RECEPTOR AGONISTS | July 2021 | October 2025 | Abandon | 52 | 2 | 1 | No | No |
| 17420287 | INDUCTION OF SUSTAINED LOCAL INFLAMMATION | July 2021 | October 2025 | Abandon | 52 | 2 | 1 | No | No |
| 17359617 | BRYOID COMPOSITIONS, METHODS OF MAKING AND USE THEREOF | June 2021 | April 2024 | Abandon | 34 | 1 | 1 | Yes | No |
| 17290111 | COMPOSITIONS AND METHODS FOR MODULATING T CELL EXHAUSTION | April 2021 | August 2025 | Abandon | 52 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BAUER, NICOLA MARIA.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 100.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner BAUER, NICOLA MARIA works in Art Unit 1621 and has examined 14 patent applications in our dataset. With an allowance rate of 50.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 51 months.
Examiner BAUER, NICOLA MARIA's allowance rate of 50.0% places them in the 12% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by BAUER, NICOLA MARIA receive 1.36 office actions before reaching final disposition. This places the examiner in the 20% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by BAUER, NICOLA MARIA is 51 months. This places the examiner in the 4% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +46.7% benefit to allowance rate for applications examined by BAUER, NICOLA MARIA. This interview benefit is in the 91% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 50.0% of applications are subsequently allowed. This success rate is in the 96% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 100.0% of cases where such amendments are filed. This entry rate is in the 98% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 133.3% are granted (fully or in part). This grant rate is in the 96% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.